Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (<scp>CLL2‐BCG</scp>): Final analysis of a multicenter, open‐label <scp>phase‐II</scp>‐trial-Reference-Cited by-同舟云学术

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial

Published:2024-04-05 Issue:6 Volume:99 Page:1192-1195
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Cramer Paula¹^ORCID,von Tresckow Julia¹²,Fink Anna‐Maria¹,Robrecht Sandra¹,Giza Adam¹,Tausch Eugen³,Müller Lothar⁴,Knauf Wolfgang⁵,Zingerle Matthias⁶,Al‐Sawaf Othman¹^ORCID,Langerbeins Petra¹^ORCID,Fischer Kirsten¹,Kreuzer Karl‐Anton¹,Kneba Michael⁷,Wendtner Clemens‐Martin⁸,Stilgenbauer Stephan³,Eichhorst Barbara¹,Hallek Michael¹

Affiliation:

1. Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne, Faculty of Medicine and University Hospital of Cologne Cologne Germany

2. Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, University of Duisburg‐Essen Essen Germany

3. Department of Internal Medicine III University Hospital Ulm Ulm Germany

4. Practice for Hematology and Oncology UnterEms Leer Germany

5. Practice for Hematology and Oncology Bethanien Frankfurt/Main Germany

6. Practice for Hematology and Oncology Pasing and Fürstenfeldbruck Munich Germany

7. Department of Internal Medicine II Campus Kiel, University of Schleswig‐Holstein Kiel Germany

8. Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine Munich Clinic Schwabing Munich Germany

Funder

Gilead Sciences

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27304

Reference5 articles.

1. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial